Daniel A Burkhoff, 66303 E 57Th St APT 36F, New York, NY 10022

6641610, Nov 4, 2003

Aug 4, 1999

09/368393

Scott J. Wolf - Minneapolis MN
Greg R. Furnish - Louisville KY
Todd A. Hall - Goshen KY
David Y. Phelps - Louisville KY
Peter J. Wilk - New York NY
Nancy C. Briefs - Nashua NH
William Santamore - Medford NJ
Daniel Burkhoff - Tenafly NJ

Percardia, Inc. - Nashua NH

A61F 206

623 13, 606153

Disclosed is a conduit that provides a bypass around a stenosis or occlusion in a coronary artery. The conduit is adapted to be positioned in the myocardium to provide a passage for blood to flow from a heart chamber to a coronary artery, at a site distal to the blockage or stenosis in the coronary artery. The conduit has a one-way valve positioned therein to prevent the backflow of blood from the coronary artery into the heart chamber.

6752771, Jun 22, 2004

Jan 29, 2001

09/772228

Neil S. Rothman - Baltimore MD
Mark Gelfand - Baltimore MD
Daniel Burkhoff - Tenafly NJ
Myron L. Weisfeldt - Irvington NY

Revivant Corporation - Sunnyvale CA

A61H 3100

601 44

A method and device are disclosed for inflating an inflatable vest to assist the heart in patients suffering from heart failure. The inflation of the vest is synchronized with on-set of the systole phase of the heart, when the left ventricular compresses to force blood out of the heart and through the aorta. The inflated vest compresses the patients chest and increases the intrathoracic pressure. This increase in pressure assists the heart in moving blood out of the heart and through the aorta. In addition, the vest is arranged to leave the patients abdomen free of restraint so that the increase in intrathoracic pressure due to the vest moves blood into the abdomen, and to allow the abdomen to dynamically recoil in response to the vest inflation. In addition, ECG signals from electrodes applied to the patient are processed to trigger the vest inflation in real time with the current heartbeat cycle, such that the vest inflation is triggered when the heart begins to contract.

6949080, Sep 27, 2005

Aug 15, 2002

10/218916

Scott J. Wolf - Minneapolis MN, US
Greg R. Furnish - Louisville KY, US
Todd A. Hall - Goshen KY, US
David Y. Phelps - Louisville KY, US
Peter J. Wilk - New York NY, US
Nancy Briefs - Nashua NH, US
William Santamore - Medford NJ, US
Daniel Burkhoff - Tenafly NJ, US
Simon Furnish - Louisville KY, US
Stephen Evans - Westford MA, US
Roger D. Kamm - Weston MA, US
Richard Renati - San Jose CA, US
Gerald Melsky - Lexington MA, US
Eun Bo Shim - Kyungbuk, KR

Percardia, Inc. - Nashua NH

A61M037/00
A61F011/00
A61F002/06
A61F002/00
A61B017/08

604 8, 606153, 606154, 606108, 623 115, 623 138, 424426

A stent suitable for implantation in myocardial tissue to enhance perfusion therein may include a tubular member having first and second ends and a lumen. The first end of the stent may be configured to pierce myocardial tissue and the lumen may be configured to be placed in flow communication with a coronary vessel. The stent may further include a means for retaining the tubular member within the myocardial tissue. A method for implanting the stent may include positioning the first end of the stent at a desired implantation site and applying force to the second end of the stent to implant the stent within the myocardial tissue. The method may further include engaging the means for retaining with the myocardial tissue to retain the stent in position.

2003011, Jun 19, 2003

Nov 19, 2002

10/299079

Daniel Burkhoff - Tenafly NJ, US

The Trustees of Columbia University

A61K048/00
C12N005/08

424/093210, 435/372000

The effects of angiogenesis created by tissue injury resulting from ischemic tissue being revascularized by transmyocardial revascularization are amplified by introducing cells containing an angiogenic agent into a patient positive to antigenic determinant such as Fik-1, Tie-2 or CD-34. Cells such as CD 34+ cells migrate to a site of angiogenesis and will thus efficiently carry the angiogenic agent to the site without requiring local introduction. Thus, a section of ischemic myocardium can be revascularized by performing TMR to create a number of sites of injury, and then introducing hematopoietic stem cells, for example CD 34+ cells, that contain a growth factor, genetic material or other angiogenic agent into the patient, most preferably by systemic introduction. As a result, the increase in vascularization will be greater than that exhibited by TMR alone or by the insertion of an angiogenic agent alone.

2003021, Nov 20, 2003

Mar 17, 2003

10/388592

Keith March - Carmel IN, US
Richard Popp - Los Altos Hills CA, US
Peter Fitzgerald - Portola Valley CA, US
Patrick Cahalan - Nashua NH, US
Daniel Burkhoff - Tenafly NJ, US
Laurence Roth - Windham NH, US
Nancy Briefs - Nashua NH, US
William Santamore - Medford NJ, US
Robert Swain - Bedford NH, US
Peter Boekstegers - Diessend A DE, US
Vincent Pompili - Chagrin Falls OH, US

A61F002/04

604/008000, 623/904000

A method for inducing vascular remodeling and related methods for treating patients having diseased vasculature. The method of inducing remodeling of the vascular system includes altering the blood flow dynamics in portions of the vascular system via mechanical mechanisms. Remodeling of certain coronary vasculature may be induced by creating a passage in a heart wall between a heart chamber and a blood vessel so as to permit blood flow communication, for example, direct blood flow communication, between the chamber and the vessel. A method of inducing vascular remodeling may include providing a blood flow passage between a heart chamber and the coronary vessel, or other flow dynamics altering structure, such that enlargement of at least a portion of the coronary vessel occurs.

2003021, Nov 20, 2003

Jun 18, 2003

10/463798

Scott Wolf - Minneapolis MN, US
Greg Furnish - Louisville KY, US
Todd Hall - Goshen KY, US
David Phelps - Louisville KY, US
Peter Wilk - New York NY, US
Nancy Briefs - Nashua NH, US
William Santamore - Medford NJ, US
Daniel Burkhoff - Tenafly NJ, US

Percardia, Inc.

A61F002/06
A61F002/04

604/008000, 623/001240, 623/023680

Disclosed is a conduit that provides a bypass around a stenosis or occlusion in a coronary artery. The conduit is adapted to be positioned in the myocardium to provide a passage for blood to flow from a heart chamber to a coronary artery, at a site distal to the blockage or stenosis in the coronary artery. The conduit has a one-way valve positioned therein to prevent the backflow of blood from the coronary artery into the heart chamber.

2004014, Jul 29, 2004

Oct 9, 2003

10/681323

Scott Wolf - Minneapolis MN, US
Greg Furnish - Louisville KY, US
Todd Hall - Goshen KY, US
David Phelps - Louisville KY, US
Peter Wilk - New York NY, US
Nancy Briefs - Nashua NH, US
William Santamore - Medford NJ, US
Daniel Burkhoff - Tenafly NJ, US
Simon Furnish - Louisville KY, US
Stephen Evans - Westford MA, US
Roger Kamm - Weston MA, US
Richard Renad - San Jose CA, US
Gerald Melsky - Lexington MA, US
Eun Shim - Kumi, KR

Percardia, Inc.

A61M005/00
A61F011/00

604/008000, 606/108000

Left ventricular conduits and related methods are disclosed for achieving bypass of a partially or completely occluded coronary artery. More broadly, conduits for allowing communication of bodily fluids from one portion of a patient's body to another and related methods are disclosed, including conduits for forming a blood flow path from a chamber of the heart to a vessel or from one vessel to another. In other embodiments, the conduits achieve a coronary artery bypass by allowing blood communication between the left ventricle and the coronary artery or between a proximal portion of the coronary artery and a distal portion of the coronary artery. The conduits may be placed completely through the heart wall or extend only partially therein. Conduits may take on a variety of configurations for allowing the control of blood flow therethrough, including curved or tapered shapes. The conduits may also follow a variety of paths, including direct transmyocardial communication between the left ventricle and the coronary artery, or through the myocardium and into the intrapericardial space and then into the coronary artery. The conduits may be implanted through a variety of methods, including minimally invasive techniques. Also disclosed are various preferred embodiments of medical devices and related methods for implanting the conduits including rigid delivery rods for penetrating bodily tissue. The delivery rods may be solid, thus being trocar-like, or hollow to form a self-implantable conduit. Other preferred rod embodiments may have the conduits mounted thereon and take the form of a stylet or the like. The conduits may be one-piece, continuous conduits or made up of a number of plural sections joined together. Disclosures of various anastomosis devices are provided.

2006011, May 25, 2006

Dec 15, 2005

11/300513

Scott Wolf - Minneapolis MN, US
Greg Furnish - Louisville KY, US
Todd Hall - Goshen KY, US
David Phelps - Louisville KY, US
Peter Wilk - New York NY, US
Nancy Briefs - Nashua NH, US
William Santamore - Medford NJ, US
Daniel Burkhoff - Tenafly NJ, US

A61M 39/24
A61F 2/04

604009000, 623023680, 623001240

Disclosed is a conduit that provides a bypass around a stenosis or occlusion in a coronary artery. The conduit is adapted to be positioned in the myocardium to provide a passage for blood to flow from a heart chamber to a coronary artery, at a site distal to the blockage or stenosis in the coronary artery. The conduit has a one-way valve positioned therein to prevent the backflow of blood from the coronary artery into the heart chamber.